Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 19;28(1):382–400. doi: 10.1038/s41418-020-00607-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a, b The 1218 breast cancer patients’ RNAseq data was divided into two groups according to the expression of AQP1. The limma R package was used to calculate the differentially expressed statistics. GO functional annotation genes in the module obtained by GSEA. Y-axis showed the GO terms and x-axis showed the gene number of each term, the degree of color represented P value. c Patients were divided into four subgroups according to the expression of both AQP1 and β-catenin. The AQP1 high/β-catenin high subgroup patients who received CEF-based therapies had a longer OS (left panel) and PFS (right panel) than non-CEF regimens (log-rank test). d The AQP1 high/β-catenin high group who received CEF-based therapies had a longer PFS (right panel) than CMF regimen patients (log-rank test). e The AQP1 high/β-catenin high group showed a longer OS (left panel) and PFS (right panel) in CEF-based therapies patients (n = 97) than the rest (i.e., the sum of AQP1 high/β-catenin low, AQP1 low/β-catenin low, and AQP1 low/β-catenin high; two-tailed Student’s t test). f The expression of AQP1 and β-catenin was detected by western blot using tumor tissues from breast cancer patients. β-actin was the loading control. g, h Co-immunoprecipitation results of AQP1 and β-catenin in breast cancer tissues (g) and Flag-AQP1/MDA-MB-231 cells (h). i Co-localization of Flag-AQP1 and β-catenin in Flag-AQP1/MDA-MB-231 cells. Insets showed a high-magnification view of the indicated region. Scale bars: 100 μm. j The expression of AQP1 and β-catenin was detected by immunohistochemistry analysis of serial paraffin sections in mice tumor tissues. Scale bars: 200 μm. Experiments (f–i) were independently repeated for three times.